{"prompt": "['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 3 of 61', 'Medtronic', '1. Investigator Statement', 'Participating investigators will be provided with a separate investigator agreement to document their', 'obligations and commitment with respect to study conduct.', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 4 of 61', 'Medtronic', 'Table of Contents', '1.', 'Investigator Statement', '3', 'Table of Contents', '4', '2. Glossary', '7', '3. Synopsis', '9', '4. Introduction', '17', '4.1. Background', '17', '4.2. Purpose', '17', '5.', 'Objectives and Enpoints', '18', '5.1. Objectives', '18', '5.1.1.', 'Primary Objective', '18', '5.1.2.', 'Secondary Objective', '18', '5.1.3.', 'Additional Measures', '18', '6.', 'Study Design', '18', '6.1. Duration', '19', '6.2. Rationale', '19', '7.', 'Product Description', '20', '7.1. General', '20', '7.2. Manufacturer', '20', '7.3. Intended Population', '20', '7.4. Product Return', '20', '7.5. Product Accountability', '20', '8.', 'Selection of Subjects', '21', '8.1. Study Population', '21', '8.2. Subject Enrollment', '21', '8.3. Inclusion Criteria', '21', '8.4 Exclusion Criteria', '21', '9.', 'Study Procedures', '22', '9.1. Schedule of Events', '23', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']['InterStim Amplitude Clinical Investigation Plan', 'MDT17030', 'Version 2.0', 'Page 5 of 61', 'Medtronic', '9.2. Subject Screening', '30', '9.3. Prior and Concomitant OAB Medications', '30', '9.4. Subject Consent', '30', '9.5. Randomization and Treatment Assignment', '31', '9.6. OAB Medication Compliance', '31', '9.7. Assessment of Efficacy', '32', '9.8. Assessment of Safety', '33', '9.9. Recording Data', '33', '9.10.', 'Deviation Handling', '33', '9.11.', 'Subject Withdrawal or Discontinuation', '34', '10. Risks and Benefits', '35', '10.1.', 'Potential Risks', '35', '10.1.1.', 'Risks Outlined in the Instructions for Use (IFU)', '35', '10.2.', 'Potential Benefits', '36', '10.3.', 'Risk-Benefit Rationale', '36', '11. Adverse Events and Device Deficiencies', '36', '11.1.', 'Definitions/Classifications', '36', '11.2.', 'Report of Adverse Events', '39', '11.2.1.', 'Device Deficiencies', '41', '11.2.2.', 'Deaths', '41', '12. Data Review Committees', '42', '13. Statistical Design and Methods', '42', '13.1 General Statistical Considerations', '42', '13.1.1', 'Study Sample Size Justification', '43', '13.1.2', 'Description of demographic and baseline variables', '44', '13.1.3', 'Center Pooling', '44', '13.1.4', 'Missing Data', '44', '13.1.5', 'Interim Analysis', '44', '13.1.6', 'Reports', '44', '13.1.7', 'Study Success', '44', '13.1.8', 'Subgroup Analyses', '44', 'Medtronic Confidential', '056-F275, v3.0 Clinical Investigation Plan Template']\n\n###\n\n", "completion": "END"}